Today, we’re officially launching with $12 million in funding, two partnerships with patient advocacy organizations, and a growing community ready to build a new way to pursue cures to rare diseases

Great discussions at #BIO2025 about AI & BD strategy. A few takeaways from our conversations at the event:.📈 BD teams want better decision support.⚡️ Speed to insight matters.🎯 The intersection of AI + human expertise is where the real edge is.Learn more

Portfolio strategy in pharma isn’t just art—or science. It’s both. Read this post to learn .🎯 Why better prioritization matters now more than ever.🧠 The hidden cost of legacy decision-making.⚡ How AI changes the game. 👉 #Biotech #Pharma #AI.

#BIO2025 — Lots of great convos about drug development. Key themes we heard:.📊 BD teams need better precision & faster turnaround.🧠 Human expertise + AI is a winning combo.🗺️ AI can help explore adjacencies & new opportunities.Want to learn more? 👉

#BIO2025 is next week + we’ll be there. If you want to talk about:.🧠 Applying AI to BD & portfolio strategy.🚀 Accelerating diligence & pipeline prioritization.🔍 How VibeOne is transforming decision-making in drug development. DM us or connect there.

Better decisions = better drugs. We recently had the opportunity to interview Jay Andersen, former Sr. Research Fellow at Eli Lilly and Company, about his experience in using statistics to drive better portfolio decisions. Read our full interview here:.

Last week, the @US_FDA dropped ELSA, a new generative AI tool for regulatory document review, a month early. → 1st use case: comparing/summarizing oncology drug submission docs.→ Faster reviews, cleaner communication, major efficiency wins.Read more:

RT @kulesatony: so excited for this. there is probably no one that has had a greater impact on the field.

RT @IAmBiotech: In just 2 weeks, over 20,000 #biotech innovators will arrive in Boston for #BIO2025, all with a shared goal - to collaborat….

RT @aloktayi: curious if lyndra's tech could make a comeback?.

RT @C_Angermayer: It has always puzzled me how much big pharma has neglected mental health. Current treatments are suboptimal at best, whi….

RT @aloktayi: if the FDA is using AI to evaluate drugs, why isn't pharma?.

RT @aloktayi: 👏 we're doing the same for biotech/pharma as well!.

🚨 Starting in 30 min!.Biopharma BD teams are under pressure to source smarter & faster. Join our webinar to learn how AI helps:. 🔍 Prioritize high-value assets. ⚖️ Benchmark competitors. ⚡️ Diligence faster—globally.Don’t miss it!.👉 #biopharma #AI #BD

RT @aloktayi: quote from a recent @Biotech2050Pod recording:."like the program, love the portfolio". this one is going to be 🔥.

RT @aloktayi: maybe just developing drugs faster and cheaper is all the disruption we need?.

RT @aloktayi: awesome to see elad going deep on therapeutics!.

RT @aloktayi: systematically collating & testing all unique MOAs & compounds for a disease is a major breakthrough.

RT @aloktayi: soooo true.

#ICYMI - Insights pharma pioneer Jay Andersen shared with @aloktayi on portfolio management & probability assessment. Great read for industry leaders interested in the 3 critical success factors in portfolio management:.#DecisionMaking #DrugDevelopment

#ICYMI - Pressure on BD&L teams stems from big industry shifts: looming #patentcliffs creating revenue gaps in #commercialportfolios + disruptive #scientificadvances that may make existing franchises obsolete. How can BD&L teams weather these challenges?.